Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties

British Journal of Pharmacology

Volumn 151, Issue 5, 2007, Pages 580-590

  Oettl, K ^a   Stauber, R E ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Albumin; Glycosylation; Ligand binding; Mercaptalbumin; Oxidative stress

Indexed keywords

ALBUMIN; BILIRUBIN; BROMOCRESOL GREEN; CARBONYL DERIVATIVE; CEFAZOLIN; CHLORMETHINE; CISPLATIN; DANSYL CHLORIDE; DIAZEPAM; FLUFENAMIC ACID; HUMAN SERUM ALBUMIN; IBUPROFEN; KETOPROFEN; LIGAND; PALMITIC ACID; PHENYLBUTAZONE; PROGESTERONE; SALICYLIC ACID; TRYPTOPHAN; VERAPAMIL; WARFARIN;

ANTIOXIDANT ACTIVITY; BINDING AFFINITY; COVALENT BOND; DISULFIDE BOND; DRUG BINDING SITE; DRUG EFFECT; DRUG OXIDATION; GLYCOSYLATION; HEPATORENAL SYNDROME; HUMAN; LIGAND BINDING; LIVER CIRRHOSIS; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW;

HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN BINDING; SERUM ALBUMIN;

EID: 34347324020     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707251     Document Type: Review

References (140)

1. Anraku M, Kitamura K, Shinohara A, Adachi M, Suenaga A, Maruyama T et al. (2004). Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 66: 841-848.
2. Anraku M, Kragh-Hansen U, Kawai K, Maruyama T, Yamasaki Y, Takakura Y et al. (2003). Validation of the Chloramine-T induced oxidation of human serum albumin as a model for oxidative damage in vivo. Pharm Res 20: 684-692.
3. Anraku M, Yamasaki K, Maruyama T, Kragh-Hansen U, Otagiri M (2001). Effect of oxidative stress on the structure and function of human serum albumin. Pharm Res 18: 632-639.
4. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J et al. (2005). Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51: 810-824.
5. Ascenzi P, Bocedi A, Notari S, Fanali G, Fesce R, Fasano M (2006). Allosteric modulation of drug binding to human serum albumin. Mini Rev Med Chem 6: 483-489.
6. Ballmer PE, Walshe D, McNurlan MA, Watson H, Brunt PW, Garlick PJ (1993). Albumin synthesis rates in cirrhosis: correlation with Child-Turcotte classification. Hepatology 18: 292-297.
7. Baron CP, Refsgaard HH, Skibsted LH, Andersen ML (2006). Oxidation of bovine serum albumin initiated by the fenton reaction - effect of EDTA, tert-butylhydroperoxide and tetrahydrofuran. Free Radic Res 40: 409-417.
8. 2+ binding amino-acid residues of the N-terminus of human albumin. Eur J Biochem 268: 42-47.
9. Bar-Or D, Heyborne KD, Bar.Or R, Rael LT, Winkler JV, Navot D (2005). Cysteinylation of maternal plasma albumin and its association with intrauterine growth restriction. Prenat Diagn 25: 245-249.
10. Bar-Or D, Winkler JV, VanBenthuysen K, Harris L, Lau E, Hetzel FW (2001b). Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am Heart J 141: 985-991.
11. Bauer C, Kuntz W, Ohnsmann F, Gasser H, Weber C, Redl H et al. (2004). The attenuation of hepatic microcirculatory alterations by exogenous subtitution of nitric oxide by S-nitroso-human albumin after hemorrhagic shock in the rat. Shock 21: 165-169.
12. Bayir H, Kochanek PM, Liu SX, Arroyo A, Osipov A, Jiang J et al. (2003). Increased S-nitrosothiols and S-nitrosoalbumin in cerebrospinal fluid after severe traumatic brain injury in infants and children: indirect association with intracranial pressure. J Cereb Blood Flow Metab 23: 51-61.
13. Beck JL, Ambahera S, Yong SR, Sheil MM, De Jersey J, Ralph SF (2004). Direct observation of covalent adducts with Cys34 of human serum albumin using mass spectrometry. Anal Biochem 325: 326-336.
14. Bertucci C, Barsotti MC, Raffaelli A, Salvadori P (2001). Binding properties of human albumin modified by covalent binding of penicillin. Biochim Biophys Acta 1544: 386-392.
15. Bertucci C, Domenici E (2002). Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr Med Chem 9: 1463-1481.
16. 34 by ethacrynic acid: structural characterisation and binding properties. J Pharm Biomed Anal 18: 127-136.
17. Bertucci C, Nanni B, Salvadori P (1999). Reversible binding of ethacrynic acid to human serum albumin: difference circular dichroism study. Chirality 11: 33-38.
18. Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H et al. (2003). Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 49: 581-585.
19. Bito R, Hino S, Baba A, Tanaka M, Watabe H, Kawabata H (2005). Degradation of oxidative stress.induced denatured albumin in rat liver endothelial cells. Am J Physiol Cell Physiol 289: C531-C542.
20. Bohney JP, Feldhoff RC (1992). Effects of nonenzymatic glycosylation and fatty acids on tryptophan binding to human serum albumin. Biochem Pharmacol 43: 1829-1834.
21. Borderie D, Allanore Y, Meune C, Devaux JY, Ekindjian OG, Kahan A (2004). High ischemia modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clin Chem 50: 2190-2193.
22. Bourdon E, Loreau N, Blache D (1999). Glucose and free radicals impair the antioxidant properties of serum albumin. FASEB J 13: 233-244.
23. Bourdon E, Loreau N, Lagrost L, Blache D (2005). Differential effects of cysteine and methionine residues in the antioxidant activity of human serum albumin. Free Radic Res 39: 15-20.
24. Burczynski FJ, Wang G-Q, Hnatowich M (1995). Effect of nitric oxide on albumin-palmitate binding. Biochem Pharmacol 49: 91-96.
25. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P (2005). LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 18: 277-287.
26. Carballal S, Radi R, Kirk MC, Barnes S, Freeman BA, Alvarez B (2003). Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite. Biochemistry 42: 9906-9914.
27. Chabner BA, Roberts TG (2005). Chemotherapy and the war on cancer. Nat Rev 5: 65-72.
28. Christodoulou J, Sadler PJ, Tucker A (1994). A new structural transition of serum albumin dependent on the state of Cys34. Eur J Biochem 225: 363-368.
29. Chujo K, Shima K, Tada H, Oohashi T, Minakuchi J, Kawashima S (2006). Indicators for blood glucose control in diabetics with end-stage chrinic renal disease: GHb vs glycated albumin (GA). J Med Invest 53: 223-228.
30. Chung KY, Lee SJ, Chung SM, Lee MY, Bae OK, Chung JH (2005). Generation of free radical by interaction of iron with thiols in human plasma and its possible significance. Thromb Res 116: 157-164.
31. Claiborne A, Yeh JI, Vallett TC, Luba J, Crane EJ, Charrier V et al. (1999). Protein-sulfenic acids: diverse roles for an unlikely player in enzyme catalysis and redox regulation. Biochemistry 38: 15407-15416.
32. Clemmesen JO, Kondrup J, Nielsen LB, Larsen FS, Ott P (2001). Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure. Am J Gastroenterol 96: 1217-1223.
33. 3PO formation. J Inorg Biochem 30: 177-187.
34. Cohen MP (2003). Intervention strategies to prevent pathogenetic effects of glycated albumin. Arch Biochem Biophys 419: 25-30.
35. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A (2003a). Protein carbonylation in human diseases. Trends Mol Med 9: 169-176.
36. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R (2003b). Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 329: 23-38.
37. Dhubhghaill OMN, Sadler PJ, Tucker A (1992). Drug-induced reactions of bovine serum albumin: 1H NMR studies of gold binding and cysteine release. J Am Chem Soc 114: 1118-1120.
38. Di Stefano G, Fiume L, Baglioni L, Busi C, Chieco P, Kratz F et al. (2006). A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation grade. Liver Int 26: 726-733.
39. Eaton JW, Qian M (2002). Interactions of copper with glycated proteins: possible involvement in the etiology of diabetic neuropathy. Mol Cell Biochem 234/235: 135-142.
40. Era S, Kuwata K, Imai H, Nakamura K, Hayashi T, Sogami M (1995). Age-related change in redox state of human serum albumin. Biochim Biophys Acta 1247: 12-16.
41. Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P et al. (2005). The extraordinary ligand binding properties of human serum albumin. IUBMB Life 57: 787-796.
42. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S (2005). Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353: 38-52.
43. Gonias SL, Pizzo SV (1983). Complex of serum albumin and cis-dichlorodiammineplatinum (II). J Biol Chem 258: 5764-5769.
44. Gryzunov YA, Arroyo A, Vigne J-L, Zhao Q, Tyurin VA, Hubel CA et al. (2003). Binding of fatty acids facilitates oxidation of cysteine-34 and converts copper-albumin complexes from antioxidants to prooxidants. Arch Biochem Biophys 413: 53-66.
45. Halliwell B, Gutteridge JMC (1999). Free Radicals in Biology and Medicine. Oxford University Press: New York.
46. Hallström S, Gasser H, Neumayer C, Flügl A, Nanobashvili J, Jakubovski A et al. (2002). S-nitroso human serum albumin treatment reduces ischemia/reperfusion injury in skeletal muscle via nitric oxide release. Circulation 105: 3032-3038.
47. Harada D, Anraku M, Fukuda H, Naito S, Harada K, Suenaga A, et al. (2004). Kinetics of covalent binding between N-acetyl-L-cysteine and human serum albumin through a mixed-disulfide using an N-methylpyridinium polymer-based column. Drug Metab Pharmacokinet 19: 297-302.
48. Hayakawa A, Kuwata K, Era S, Sogami M, Shimonaka H, Yamamoto M et al. (1997). Alteration of redox state of human srum albumin in patients under anesthesia and invasive surgery. J Chromatogr B 698: 27-33.
49. Hayashi T, Era S, Kawai K, Imai H, Nakamura K, Onda E et al. (2000). Obersvation for redox stat of human serum and aqueous humor albumin from patients with senile cataract. Pathophysiology 6: 237-243.
50. Hider RC (2002). Nature of nontransferrin-bound iron. Eur J Clin Invest 32S1: 50-54.
51. Himmelfarb J, McMonagle E (2001). Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 60: 358-363.
52. Imai H, Hayashi T, Negawa T, Nakamura K, Tomida M, Koda K et al. (2002). Strenous exercise-induced change in redox state of human serum albumin during intensive kendo training. Jpn J Physiol 52: 135-140.
53. Ivanov AI, Christodoulou J, Parkinson JA, Barnham KJ, Tucker A, Woodrow J et al. (1998). Cisplatin binding sites on human albumin. J Biol Chem 273: 14721-14730.
54. Iwao Y, Anraku M, Hiraike M, Kawai K, Nakajou K, Kai T et al. (2006a). The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP). Drug Metab Pharmacokinet 21: 140-146.
55. Iwao Y, Anraku M, Yamasaki K, Kragh-Hansen U, Kawai K, Maruyama T et al. (2006b). Oxidation of Arg-410 promotes the elimination of human serum albumin. Biochim Biophys Acta 1764: 743-749.
56. Jalan R, Williams R (2002). Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 20: 252-261.
57. Jones DP (2006). Extracellular redox state: refining the definition of oxidative stress in aging. Rejuv Res 9: 169-181.
58. Jones DP, Mody VC, Carlson JL, Lynn MJ, Sternberg P (2002). Redox analysis of human plasma allows separation of pro-oxidant events of aging from decline in antioxidant defenses. Free Radic Biol Med 33: 1290-1300.
59. Jourd'Heuil D, Hallén K, Feelisch M, Grisham MB (2000). Dynamic state of S-nitrosothiols in human plasma and whole blood. Free Radic Biol Med 28: 409-417.
60. Kadota K, Yui Y, Hattori R, Murohara Y, Kawai C (1991). Decreased sulfhydryl groups of serum albumin in coronary artery disease. Jpn Circ J 55: 937-941.
61. Karp WB, Kinsley M, Subramanyam SB, Robertson AF (1985). Binding properties of glycosylated albumin and acetaldehyde albumin. Alcohol Clin Exp Res 9: 429-432.
62. Kashiba-Iwatsuki M, Miyamoto M, Inoue M (1997). Effect of nitric oxide on the ligand-binding activity of albumin. Arch Biochem Biophys 345: 237-242.
63. Kawakami A, Kubota K, Yamada N, Tagami U, Takehana K, Sonaka I et al. (2006). Identification and characterization of oxidized human serum albumin. FEBS J 273: 3346-3357.
64. Keany JF, Simon DI, Stamler JS, Jaraki O, Scharfstein J, Vita JA, et al. (1993). NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest 91: 1582-1589.
65. Klammt S, Brinkmann B, Mitzner S, Munzert E, Loock J, Stange J et al. (2001). Albumin binding capacity (ABiC) is reduced in commercially available human serum albumin preparations with stabilizers. Z Gastroenterol Suppl2 39: 24-27.
66. 31P nuclear magnetic resonance and fluorescence study of the interaction of an antiarthritic gold phosphine drug with albumin. Inorg Chim Acta 91: 263-267.
67. Koizumi K, Ikeda C, Ito M, Suzuki J, Kinoshita T, Yasukawa K et al. (1998). Influence of glycosylation on the drug binding of human serum albumin. Biomed Chromatogr 12: 203-210.
68. Koyama H, Sugioka N, Uno A, Mori S, Nakajima K (1999). Age-related alteration of carbamazepine-serum protein binding in man. J Pharm Pharmacol 51: 1009-1914.
69. Kragh-Hansen U (1981). Molecular aspects of ligand binding to serum albumin. Pharmacol Rev 33: 17-53.
70. Kragh-Hansen U (1990). Structure and ligand binding properties of human serum albumin. Dan Med Bull 37: 57-84.
71. Kragh-Hansen U, Chuang VTA, Otagiri M (2002). Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 25: 695-704.
72. Kragh-Hansen U, Donaldson D, Jensen PH (2001). The glycan structure of albumin Redhill, a glycosylated variant of human serum albumin. Biochim Biophys Acta 1550: 20-26.
73. Kragh-Hansen U, Pedersen AO, Galliano M, Minchiotti L, Brennan SO, Tárnoky AL et al. (1996). High-affinity binding of laurate to naturally occurring mutants of human serum albumin and proalbumin. Biochem J 320: 911-916.
74. Kratochwil NA, Ivanov AI, Patriarca M, Parkinson JA, Gouldsworthy AM, Murdoch P et al. (1999). Surprising reactions of Iodo Pt(IV) and Pt(II) complexes with human albumin: detection of Cys34 sulfenic acid. J Am Chem Soc 121: 8193-8203.
75. Kratz F, Muller-Driver R, Hofmann I, Drevs J, Unger C (2000). A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem 43: 1253-1256.
76. Kratz F, Warnecke A, Scheuermann K, Stockmar C, Schwab J, Lazar P et al. (2002). Probing the cystein-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 45: 5523-5533.
77. Lee DH, Liu DY, Jacobs DR, Shin HR, Song K, Lee IK et al. (2006). Common presence of non-transferrin-bound iron among patients with type 2 diabetes. Diabetes Care 29: 1090-1095.
78. Le Lan C, Loréal O, Cohen T, Ropert M, Glickstein H, Lainé F et al. (2005). Redox active plasma iron in C282Y/X282Y hemochromatosis. Blood 105: 4527-4531.
79. Levine R (2002). Carbonyl modified proteins in cellular regulation, aging, and disease. Free Radic Biol Med 32: 790-796.
80. Marley R, Patel RP, Orie N, Ceaser E, Darley-Usmar V, Moore K (2001). Formation of nanomolar concentrations of S-nitrosoalbumin in human plasma by nitric oxide. Free Radic Biol Med 31: 688-696.
81. Masuoka J, Hegenauer J, Van Dyke R, Saltman P (1993). Intrinsic stoichiometric equilibrium constants for the binding of zinc(II) and copper (II) to the high affinity site of serum albumin. J Biol Chem 268: 21533-21537.
82. Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, Otagiri M (2005). The structure and function of oxidized albumin in hemodialysis patients: its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 334: 1322-1328.
83. Meucci E, Mordente A, Martorana GE (1991). Metal-catalyzed oxidation of human serum albumin: conformational and functional changes. J Biol Chem 266: 4692-4699.
84. Michelis R, Gery R, Sela S, Shurtz-Swirski R, Grinberg N, Snitkovski T et al. (2003). Carbonyl stress induced by intravenous iron during haemodialyis. Nephrol Dial Transplant 18: 924-930.
85. Mirza UA, Chait BT, Lander HM (1995). Monitoring reactions of nitric oxide with peptides and proteins by electrospray ionization-mass spectrometry. J Biol Chem 270: 17185-17188.
86. Moriarty-Craige SE, Jones DP (2004). Extracellular thiols and thiol/disulfide redox in metabolism. Annu Rev Nutr 24: 481-509.
87. Muramoto Y, Matsushita M, Irino T (1999). Reduction of reaction differences between human mercaptalbumin and human nonmercaptalbumin measured by the bromcresol purple method. Clin Chim Acta 289: 69-78.
88. Nakajou K, Watanabe H, Kragh-Hansen U, Maruyama T, Otagiri M (2003). The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. Biochim Biophys Acta 1623: 88-97.
89. Narazaki R, Harada K, Sughi A, Otagiri M (1997). Kinetic analysis of the covalent binding of captopril to human serum albumin. J Pharmaceut Sci 86: 215-219.
90. Narazaki R, Otagiri M (1997). Covalent binding of a bucillamine derivative with albumin in sera from healthy subjects and patients with various diseases. Pharm Res 14: 351-353.
91. Ng ESM, Jourd'heuil D, McCord JM Hernandez D, Yasui M, Knight D, Kubes P (2004). Enhanced S-nitroso-albumin formation from inhaled NO during ischemia/reperfusion. Circ Res 94: 559-565.
92. Nielsen H, Kragh-Hansen U, Minchiotti L, Galliano M, Brennan SO, Tárnoky AL et al. (1997). Effect of genetic variation on the fatty acid binding properties of human serum albumin and proalbumin. Biochim Biophys Acta 1342: 191-204.
93. Noort D, Hulst AG, DeJong LPA, Benschop HP (1999). Alkylation of human serum albumin by sulphur mustard in vitro and in vivo: mass spectrometric analysis of a cysteine adduct as a sensitive biomarker of exposure. Chem Res Toxicol 12: 715-721.
94. Noort D, Hulst AG, Jansen R (2002). Covalent binding of nitrogen mustards to the cysteine-34 residue in human serum albumin. Arch Toxicol 76: 83-88.
95. Oettl K, Greilberger J, Stadlbauer V, Petter F, Lackner C, Putz-Bankuti C et al. (2006). Redox state of serum albumin and carbonyl content of plasma proteins in advanced liver disease. Proceedings of the 13th Biennal Congress of the Society for Free Radical Research International. Medimond: Bologna, pp 265-268.
96. Ogasawara Y, Mukai Y, Togawa T, Suziki T, Tanabe S, Ishij K (2007). Determination of plasma thiol bound to albumin using affinity chromatography and high-performance liquid chromatography with fluorescence detection: ratio of cysteinyl albumin as a possible biomarker of oxidative stress. J Chromatogr B 845: 157-163.
97. Ogino T, Okada S (1995). Oxidative damage of bovine serum albumin and other enzyme proteins by iron-chelate complexes. Biochim Biophys Acta 1245: 359-365.
98. Okabe N, Hashizume N (1994). Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism. Biol Pharm Bull 17: 16-21.
99. Orie NN, Vallance P, Jones DP, Moore KP (2005). S-nitroso-albumin carries a thiol-labile pool of nitric oxide, which causes venodilation in the rat. A J Physiol Heart Circ Physiol 289: H916-H923.
100. Otagiri M (2005). A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet 20: 309-323.
101. Ottesen LH, Harry D, Frost M, Davies S, Khan K, Halliwell B et al. (2001). Increased formation of S-nitrosothiols and nitrotyrosine in cirrhotic rats during endotoxemia. Free Radic Biol Med 31: 790-798.
102. Perna AF, Satta D, Lombardi C, Ingrosso D, De Santo NG (2006). Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int 69: 869-876.
103. Peters T (1996). All About Albumin; Biochemistry, Genetics and Medical Applications. Academic Press: San Diego, CA.
104. Pizzo SV, Swaim MW, Roche PA, Gonias SL (1988). Selectivity and stereospecificity of the reactions of dichlorodiammineplatinum(II) with three purified plasma proteins. J Inorg Biochem 33: 67-76.
105. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI (2004). Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/HbE patients treated with an oral chelator. Blood 104: 1504-1510.
106. Qiu Y, Burlingame AL, Benet LZ (1998). Mechanism for covalent binding of benoxaprofen glucuronide to human serum albumin. Drug Metab Dispos 26: 246-256.
107. Raghunand N, Jagadish B, Trouard TP, Galons J-P, Gillies RJ, Mash EA (2006). Redox-sensitive contrast agents for MRI based on reversible binding of thiols to serum albumin. Magn Reson Med 55: 1272-1280.
108. Rifai K, Manns MP (2006). Review article: clinical experience with Prometheus. Ther Apher Dial 10: 132-137.
109. Roberts JR, Xiao J, Schliesman B, Parsons DJ, Shaw CF (1996). Kinetics and mechanism of the reaction between serum and auranofin (and its isopropyl analogue) in vitro. Inorg Chem 35: 424-433.
110. Rozga J, Umehara Y, Trofimenko A, Sadahiro T, Demetriou AA (2006). A novel plasma filtration therapy for hepatic failure: preclinical studies. Ther Apher Dial 10: 138-144.
111. Scharfstein JS, Keaney JF, Slivka A, Welch GN, Vita JA, Stamler JS et al. (1994). J Clin Invest 94: 1432-1439.
112. Scorza G, Pietraforte D, Minetti M (1997). Role of ascorbate and protein thiols in the release of nitric oxide from S-nitroso-albumin and S-nitroso-glutathion in human plasma. Free Radic Biol Med 22: 633-642.
113. Semroth S, Fellner B, Trescher K, Bernecker OY, Kalinowski L, Gasser H, et al. (2005). S-nitroso human serum albumin attenuates ischemia/reperfusion injury after cardioplegic arrest in isolated rabbit hearts. J Heart Lung Transplamant 24: 2226-2234.
114. Shacter EY, Williams JA, Lim M, Levine RL (1994). Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med 17: 429-437.
115. Shaklai N, Garlick RL, Bunn HF (1984). Nonenzymatic glycosylation of human serum albumin alters its conformation and function. J Biol Chem 259: 3812-3817.
116. Shaw CF (1989). The protein chemistry of antiarthritic gold(I) thiolates and related complexes. Comments Inorg Chem 8: 233-267.
117. Simard JR, Zunszain PA, Hamilton JA, Curry S (2006). Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analyses. J Mol Biol 361: 336-351.
118. Singh RJ, Hogg N, Joseph J, Kalyanaraman B (1996). Mechanism of nitric oxide release from S-nitrosothiols. J Biol Chem 271: 18596-18603.
119. Soejima A, Matsuzawa N, Hayashi T, Kimura R, Ootsuka T, Fukuoka K et al. (2004). Alteration of redox state of human albumin before and after hemodialysis. Blood Purif 22: 525-529.
120. Sogami M, Era S, Nagaoka Sm Kuwata K, Kida K, Shigami J, Miura K et al. (1985). High-performance liquid chromatographic studies on non-mercapt - mercapt conversion of human serum albumin II. J Chromatogr 332: 19-27.
121. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L et al. (1999). Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341: 403-409.
122. Stamler JS (2004). S-nitrosothiols in the blood. Roles, amounts, and methods of analysis. Circ Res 94: 414-417.
123. Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH (2002). The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 26: 103-110.
124. Sudlow G, Birkett DJ, Wade DN (1976). Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol 12: 1052-1061.
125. Stoyanovsky DA, Tyurina YY, Tyurin VA, Anand D, Mandavia DN, Gius D et al. (2005). Thioredoxin and lipoic acid catalyze the denitrosation of low molecular weight and protein S-nitrosothiols. J Am Chem Soc 127: 15815-15823.
126. Suzuki E, Yasuda K, Takeda N, Sakata S, Era S, Kuwata K et al. (1992). Increased oxidized form of human serum albumin in patients with diabetes mellitus. Diabetes Res Clin Pract 18: 153-158.
127. Szapacs ME, Riggins JN, Zimmerman LJ, Liebler DC (2006). Covalent adduction of human serum albumin by 4-hydroxy-2-nonenal: kinetic analysis of competing alkylation reactions. Biochemistry 45: 10521-10528.
128. 99mTc-DL-homocysteine, a model compound for the development of tumor-imaging radiopharmaceuticals. Int J Rad Appl Instrum B 17: 751-755.
129. 99mTc-complex to tumor tissue. Nucl Med Biol 18: 499-502.
130. 99mTc-DL-homocysteine by cooperative use of SH-containing compounds. Med Biol Nucl 16: 581-585.
131. - to human serum albumin. J Biol Inorg Chem 11: 559-570.
132. Temple A, Yen TY, Gronert S (2006). Identification of specific protein carbonylation sites in model oxidations of human serum albumin. J Am Soc Mass Spectrom 17: 1172-1180.
133. Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, Yamada K et al. (2004). Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 66: 1988-1993.
134. Timerbaev AR, Aleksenko SS, Polec-Pawlak K, Ruzik R, Semenova O, Hartinger CG et al. (2004). Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin. Electrophoresis 25: 1988-1995.
135. Tsikas D, Frölich JC (2002). S-nitrosoalbumin plasma levels in health and disease: facts or artefacts? Value of analytical chemistry in nitric oxide clinical research. Circ Res 90: e39.
136. 2+ via intermiediate formation of S-nitrosocysteine and nitric oxide. J Chromatogr B 772: 335-346.
137. Tsikas D, Sandmann J, Lueßen P, Savva A, Rossa S, Stichtenoth DO et al. (2001). S-transnitrosylation of albumin in human plasma and blood in vitro and in vivo in the rat. Biochim Biophys Acta 1546: 422-434.
138. Watanabe A, Matsuzaki S, Moriwaki H, Suzuki K, Nishiguchi S (2004). Problems in serum albumin measurement and clinical significance of albumin microheterogeneity in cirrhotics. Nutrition 20: 351-357.
139. Wörner W, Pfleiderer S, Kratzer W, Rietbrock N (1990). Nonenzymatic glycation of human serum albumin: influence on the binding kinetics of the benzodiazepine binding site. J Clin Chem Clin Biochem 28: 527-531.
140. Zhang Y, Hogg N (2005). S-nitrosothiols: cellular formation and transport. Free Radic Biol Med 38: 831-838.